Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Tyra Biosciences, maintaining a price target of $28.
October 25, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Tyra Biosciences, maintaining a price target of $28.
The reiteration of an Outperform rating and a maintained price target of $28 by Wedbush is a positive signal for Tyra Biosciences. This suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100